natgillin/translations-raw huggingface dataset:
Common: may affect up to 1 in 10 people - Hypoglycaemia is common when dulaglutide is used alone, or with both metformin and pioglitazone together, or with a sodium-glucose co-transporter 2 inhibitor (SGLT2i) with or without metformin. 
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov - hipoglikemija je pogosta bodisi ob uporabi dulaglutida samega, sočasno z metforminom in pioglitazonom ali sočasno z zaviralcem natrijevih glukoznih koprenašalcev 2 (zaviralcem SGLT2) in z metforminom ali brez metformina.
Trulicity is used: - on its own if your blood sugar is not properly controlled by diet and exercise alone, and you can't take metformin (another diabetes medicine). 
Zdravilo Trulicity se uporablja: - samostojno, če vaš krvni sladkor ni ustrezno uravnan samo z dieto in telesno vadbo in ne smete jemati metformina (drugo zdravilo za zdravljenje sladkorne bolezni).
Age had no clinically relevant effect on the pharmacokinetic and pharmacodynamic properties of dulaglutide. 
Starost ni imela klinično pomembnega učinka na farmakokinetične in famakodinamične lastnosti dulaglutida.
Treatment of rats throughout pregnancy and lactation produced memory deficits in female offspring at exposures that were 16-fold higher than those proposed clinically. 
Odmerjanje dulaglutida ves čas brejosti in laktacije podgan je povzročilo okvare spomina pri mladičih ženskega spola pri 16-kratniku izpostavljenosti človeka pri predlagani klinični uporabi.
Combination therapy with metformin 
Kombinirano zdravljenje z metforminom
- Hypoglycaemia (low blood sugar) is very common when dulaglutide is used with medicines that contain metformin, a sulphonylurea and/or insulin. 
- hipoglikemija (nizek krvni sladkor) je zelo pogosta ob sočasni uporabi dulaglutida z zdravili, ki vsebujejo metformin, sulfonilsečnino in/ali insulin.
If you forget to use Trulicity 
Če ste pozabili vzeti zdravilo Trulicity
There were significantly fewer patients in the Trulicity group who received an additional glycaemic intervention compared to placebo (Trulicity: 2,086 [42.2 %]; placebo: 2,825 [57.0 %]; p < 0.001). 
V primerjavi s skupino, ki je prejemala placebo, je pomembno manj bolnikov v skupini, ki je prejemala zdravilo Trulicity, prejelo dodatno intervencijsko zdravilo za nadzor glikemije (zdravilo Trulicity: 2086 [42,2 %]; placebo: 2825 [57,0 %]; p < 0,001).
In studies of 26 weeks duration, the incidence of discontinuation due to adverse events was 2.6% (0.75 mg) and 6.1% (1.5 mg) for dulaglutide versus 3.7 % for placebo. 
V študijah, ki so trajale 26 tednov, je bila incidenca prekinitev zaradi neželenih dogodkov 2,6 % (0,75 mg) in 6,1% (1,5 mg) za dulaglutid v primerjavi s 3,7 % za placebo.
INFORMATION IN BRAILLE TRULICITY 0.75 mg 
PODATKI V BRAILLOVI PISAVI TRULICITY 0,75 mg
In the same study, a single 1.5 mg dose of dulaglutide appeared to increase maximal insulin secretion from the β-cells, and to enhance β-cell function in subjects with type 2 diabetes mellitus as compared with placebo. 
V isti študiji je enkratni odmerek dulaglutida 1,5 mg povečal največje izločanje insulina iz β-celic ter povečal delovanje β-celic pri preskušancih s sladkorno boleznijo tipa 2 v primerjavi s placebom.
In a meta-analysis of phase II and III registration studies, a total of 51 patients (dulaglutide: 26 [N = 3,885]; all comparators: 25 [N = 2,125]) experienced at least one cardiovascular (CV) event (death due to CV causes, nonfatal MI, nonfatal stroke, or hospitalisation for unstable angina). 
V metaanalizi registracijskih študij 2. in 3. faze je skupno 51 bolnikov (dulaglutid: 26 [N = 3885]; vsa primerjalna zdravila: 25 [N = 2125]) doživelo vsaj en kardiovaskularni (KV) dogodek (smrt zaradi KV
These studies included 3,808 dulaglutide treated patients, of whom 2,250 were treated with Trulicity 1.5 mg weekly and 1,558 were treated with Trulicity 0.75 mg weekly. 
Te študije so vključevale 3808 bolnikov, zdravljenih z dulaglutidom, od katerih je bilo 2250 bolnikov tedensko zdravljenih z zdravilom Trulicity 1,5 mg, 1558 pa jih je bilo tedensko zdravljenih z zdravilom Trulicity 0,75 mg.
None of the patients with systemic hypersensitivity developed dulaglutide anti-drug antibodies. 
Pri nobenem od bolnikov s sistemsko preobčutljivostjo se niso razvila protitelesa proti dulaglutidu.
Trulicity has no or negligible influence on the ability to drive or use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Trulicity nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
2 PLACE AND UNLOCK 
2 NAMESTITE IN ODKLENITE
If the injection is given by someone else, they may inject in your upper arm. 
Če vam injekcijo da druga oseba, vam zdravilo lahko injicira v vašo nadlaket.
You should receive training from your doctor, pharmacist or nurse on the right way to prepare and inject your medicine. 
Zdravnik, farmacevt ali medicinska sestra vas bodo ustrezno poučili o pravilnem načinu priprave in injiciranja zdravila.
However, no trend in dulaglutide exposure was observed relative to the degree of hepatic impairment. 
Kljub temu niso opazili trenda izpostavljenosti dulaglutidu glede na stopnjo okvarjenosti jetrnega delovanja.
* Documented, symptomatic hypoglycaemia with blood glucose ≤ 3.9 mmol/L † Dulaglutide 1.5 mg dose only. 
* Dokumentirana simptomatska hipoglikemija s krvno glukozo ≤ 3,9 mmol/l.
If less than 3 days (72 hours) remain before the next scheduled dose, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. 
Če so do naslednjega predpisanega odmerka ostali manj kot 3 dnevi (72 ur), je treba zamujeni odmerek preskočiti, naslednji odmerek pa dati na naslednji predpisani dan.
The safety and efficacy of dulaglutide was also investigated in an active controlled study (liraglutide 1.8 mg daily) of 26 weeks duration, both in combination with metformin. 
Varnost in učinkovitost dulaglutida so preučevali tudi študiji, nadzorovani z aktivno primerjavo (liraglutid 1,8 mg na dan), ki je trajala 26 tednov, obakrat v kombinaciji z metforminom.
Additionally, in a 52-week clinical study in patients with type 2 diabetes and moderate to severe renal impairment (eGFR [by CKD-EPI] <60 and ≥15 mL/min/1.73 m2), the pharmacokinetic profile of Trulicity 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies. 
Poleg tega je bil v 52-tedenski klinični študiji, ki je vključila bolnike s sladkorno boleznijo tipa 2 in z zmerno do hudo okvaro delovanja ledvic (eGFR [po CKDEPI] < 60 in ≥ 15 ml/min/1,73 m2) farmakokinetični profil zdravila Trulicity 0,75 mg in 1,5 mg, danega enkrat na teden, podoben tistemu, ki so ga dokazali v predhodnih kliničnih študijah.
The safety and efficacy of dulaglutide was investigated in a placebo and active controlled (sitagliptin 100 mg daily) study of 104 weeks duration, all in combination with metformin. 
Varnost in učinkovitost zdravila Trulicity sta bili raziskani v študiji, nadzorovani s placebom in aktivno primerjavo (sitagliptin 100 mg na dan), ki je trajala 104 tedne, vedno v kombinaciji z metforminom.
Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. 
Dulaglutid zakasni praznjenje želodca in lahko vpliva na hitrost absorpcije sočasno vzetih peroralnih zdravil.
• Inject your dose using another syringe. 
• Svoj odmerek si injicirajte z drugo injekcijsko brizgo.
It is important to avoid dehydration by drinking plenty of fluids. 
Pomembno je, da pijete veliko tekočine in se tako izognete dehidraciji.
If the pen has been frozen, DO NOT USE. 
Če je bil peresnik zamrznjen, GA NE UPORABITE.
Dulaglutide coadministration with sitagliptin increased dulaglutide exposure and Cmax by approximately 38 % and 27 %, respectively, and median tmax increased approximately 24 hours. 
Sočasno dajanje dulaglutida in sitagliptina je povečalo izpostavljenost dulaglutidu in Cmax za približno 38 % in 27 %, mediani tmax pa je naraščal v obdobju približno 24 ur.
There was a general increase in tmax of dulaglutide with increased hepatic impairment. 
Opazili so tudi splošno povečanje časa tmax dulaglutida ob povečani okvari delovanja jeter.
No dosage adjustment is required in patients with mild, moderate or severe renal impairment (eGFR <90 to ≥15 mL/min/1.73m2). 
Pri bolnikih z blago, zmerno ali hudo okvarjenim delovanjem ledvic (eGFR < 90 do ≥ 15 ml/min/1,73m2) prilagoditev odmerka ni potrebna.
Do not use this medicine after the expiry date which is stated on the pen label and on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na oznaki peresnika in na škatli poleg oznake „Uporabno do/EXP“.
When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued. 
Če je zdravilo Trulicity dodano obstoječemu zdravljenju z metforminom in/ali zaviralcem natrijevih glukoznih koprenašalcev 2 (SGLT2), je mogoče nadaljevati s trenutnim odmerkom metformina in/ali zaviralca SGLT2.
Glass syringe (type I) encased in a disposable pen. 
Steklena brizga (tip I) je vložena v peresnik za enkratno uporabo.
It should not be administered intravenously or intramuscularly. 
Zdravila Trulicity se ne sme aplicirati intravensko ali intramuskularno.
Do not put the needle cover back on - this may result in an accidental needle stick injury to your hand. 
• Ne nameščajte znova pokrovčka igle - to bi lahko povzročilo poškodbo vaše dlani zaradi vboda z iglo.
- you are taking a sulphonylurea or insulin for your diabetes, as low blood sugar (hypoglycaemia) can occur. 
- jemljete sulfonilsečnino ali insulin za zdravljenje vaše sladkorne bolezni, saj lahko pride do nizkega krvnega sladkorja (hipoglikemija).
Following coadministration with 2 consecutive doses of dulaglutide, sitagliptin AUC(0-τ) and Cmax decreased by approximately 7.4 % and 23.1 %, respectively. 
Po sočasnem dajanju z dvema zaporednima odmerkoma dulaglutida sta se AUC(0-τ) in Cmax sitagliptina zmanjšala za približno 7,4 % in 23,1 %.
Following a first dose of 1 and 3 mg dulaglutide, paracetamol Cmax was reduced by 36 % and 50 %, respectively, and the median tmax occurred later (3 and 4 hours, respectively). 
Po prvem odmerku 1 in 3 mg dulaglutida se je največja koncentracija Cmax paracetamola znižala za 36 % in 50 %, mediana časa do maksimalne serumske koncentracije tmax pa je nastopila pozneje (3 in 4 ure pozneje).
Storage and Handling Disposal of Pen Commonly Asked Questions Other Information Where to Learn More 
Shranjevanje in rokovanje Odlaganje peresnika Pogosto zastavljena vprašanja Druge informacije
In addition, there was significantly lower perceived frequency of hyperglycaemia and hypoglycaemia compared to exenatide twice daily. 
Poleg tega so bolniki navedli značilno nižjo zaznano pogostnost hiperglikemije in hipoglikemije v primerjavi z eksenatidom dvakrat na dan.
Patients at target HbA1c 
Bolniki, ki so dosegli ciljno vrednost HbA1c
Sitagliptin tmax increased approximately 0.5 hours following coadministration with dulaglutide compared to sitagliptin alone. 
tmax sitagliptina se je povečal približno 0,5 ure po sočasnem dajanju dulaglutida v primerjavi z dajanjem samega sitagliptina.
Place the clear base flat and firmly against your skin at the injection site. 
• Prozorno podnožje plosko in trdno namestite na kožo na mestu injiciranja.
INFORMATION IN BRAILLE TRULICITY 1.5 mg 
PODATKI V BRAILLOVI PISAVI TRULICITY 1,5 mg
When it is added to existing therapy of a sulphonylurea or insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see sections 4.4 and 4.8). 
Če je zdravilo Trulicity dodano obstoječemu zdravljenju s sulfonilsečnino ali insulinu, je treba razmisliti o zmanjšanju odmerka sulfonilsečnine ali insulina za zmanjšanje tveganja hipoglikemije (glejte poglavji 4.4 in 4.8).
Trulicity can be taken out of the fridge for up to 14 days at a temperature not above 30ºC. 
Zdravilo Trulicity lahko vzamete iz hladilnika in ga hranite pri temperaturi, ki ne presega 30 °C, največ 14 dni.
If you stop using Trulicity 
Če ste prenehali jemati zdravilo Trulicity
Change in body weight 
Sprememba v telesni masi
Trulicity contains sodium 
Zdravilo Trulicity vsebuje natrij
When it is used in combination with a sulphonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4). 
Bolnike je treba opozoriti, naj ob uporabi zdravila Trulicity v kombinaciji s sulfonilsečnino ali insulinom upoštevajo previdnostne ukrepe, da se izognejo hipoglikemiji med vožnjo in upravljanjem s stroji (glejte poglavje 4.4).
The instructions for using the syringe, included with the package leaflet, must be followed carefully. 
Navodila za uporabo injekcijske brizge, ki so priložena navodilu za uporabo zdravila, je treba natančno upoštevati.
When initiating treatment with Trulicity, you may in some cases experience loss of fluids/dehydration, e.g. in case of vomiting, nausea and/or diarrhoea which may lead to a decrease in kidney function. 
Pri uvedbi zdravljenja z zdravilom Trulicity morda lahko pride do izgube tekočine/dehidracije, npr. ob bruhanju, slabosti in/ali driski, kar lahko privede do zmanjšanega delovanja ledvic.
Dulaglutide was studied in a 52 week active controlled monotherapy study in comparison to metformin. 
Dulaglutid so preučevali v 52-tedenski aktivno nadzirani študiji monoterapije v primerjavi z metforminom.
After coadministration of steady state digoxin with 2 consecutive doses of dulaglutide, overall exposure (AUCτ) and tmax of digoxin were unchanged; and Cmax decreased by up to 22 %. 
Po sočasnem dajanju digoksina v stanju dinamičnega ravnovesja in dveh zaporednih odmerkov dulaglutida sta celokupna izpostavljenost (AUCτ) in tmax digoksina ostala nespremenjena, Cmax digoksina pa se je zmanjšal do 22 %.
Steady-state plasma concentrations were achieved between 2 to 4 weeks of once-weekly administration of dulaglutide (1.5 mg). 
Plazemske koncentracije v stanju dinamičnega ravnovesja so bile dosežene po 2 do 4 tednih aplikacije dulaglutida (1,5 mg) enkrat na teden.
For complete information about proper storage, read the Information for the patient. 
Za celotne informacije o primernem shranjevanju preberite Navodilo za uporabo.
atrioventricular block (AVB) 
Preiskave sinusna tahikardija, atrioventrikularni blok prve stopnje (AVB)
These changes are consistent with the gastric emptying delay of dulaglutide and within the pharmacokinetic variability of metformin and thus are not clinically relevant. 
povzročeno z dulaglutidom in so zajete v farmakokinetični variabilnosti metformina, zato niso klinično pomembne.
The dose can be administered at any time of day, with or without meals. 
Odmerek se lahko aplicira v katerem koli delu dneva, neodvisno od obrokov hrane.
LIST OF EXCIPIENTS Excipients: Sodium citrate; citric acid, anhydrous; mannitol; polysorbate 80; water for injections 
Pomožne snovi: natrijev citrat, brezvodna citronska kislina, manitol, polisorbat 80, voda za injekcije.
This medicine contains less than 1 mmol sodium (23 mg) per 0.75 mg or 1.5 mg, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 0,75 mg ali 1,5 mg, kar v bistvu pomeni »brez natrija«.
But be sure to choose a different injection site within that area. 
vendar pa morate na tem delu izbirati različna mesta injiciranja.
What if there is a drop of liquid on the tip of the needle when I remove the needle cover? 
Kaj če opazim kapljico tekočine na konici igle, ko odstranim pokrovček igle?
Gently release the skin. 
• Nežno izpustite kožno gubo.
Following dulaglutide coadministration, S- and R-warfarin exposure and R-warfarin Cmax were unaffected, and S-warfarin Cmax decreased by 22 %. 
Po sočasni aplikaciji dulaglutida ni prišlo do vpliva na izpostavljenost S- in R-varfarina ter na Cmax za Rvarfarin, opazili pa so 22% zmanjšanje Cmax S-varfarina.
The mean absolute bioavailability of dulaglutide following single-dose subcutaneous administration of single 1.5 mg and 0.75 mg doses was 47 % and 65%, respectively. 
Povprečna absolutna biološka uporabnost dulaglutida po subkutani aplikaciji enkratnih odmerkov 1,5 mg in 0,75 mg je bila 47 % in 65 %.
Heart rate increase 
- povečan srčni utrip
Another person may give you the injection in your upper arm. 
• Druga oseba vam lahko da injekcijo v nadlaket.
Storage and Handling Disposal of Syringe Commonly Asked Questions Other Information Where to Learn More 
Shranjevanje in rokovanje Odlaganje injekcijske brizge Pogosto zastavljena vprašanja Druge informacije
Coadministration of multiple dulaglutide doses with steady state lisinopril caused no clinically relevant changes in the AUC or Cmax of lisinopril. 
Ko so aplicirali več odmerkov dulaglutida s sočasno aplikacijo lisinoprila v stanju dinamičnega ravnovesja, to ni klinično pomembno vplivalo na AUC ali Cmax lisinoprila.
The mean baseline dose of insulin glargine was 37 units/day for patients receiving placebo and 41 units/day for patients receiving Trulicity 1.5mg. 
Povprečni izhodiščni odmerek insulina glargina je bil 37 enot/dan za bolnike, ki so prejemali placebo, in 41 enot/dan za bolnike, ki so prejemali zdravilo
The most frequent adverse reactions leading to discontinuation for 0.75 mg and 1.5 mg dulaglutide, respectively, were nausea (1.0%, 1.9 %), diarrhoea (0.5%, 0.6 %), and vomiting (0.4%, 0.6 %), and were generally reported within the first 4-6 weeks. 
Najpogostejši neželeni učinki, zaradi katerih je prišlo do prekinitve za dulaglutid v odmerkih 0,75 mg in 1,5 mg so bili slabost (1,0 % oziroma 1,9 %), driska (0,5 % oziroma 0,6 %) in bruhanje (0,4 % oziroma 0,6 %), o njih pa so na splošno poročali v prvih 4-6 tednih.
Dulaglutide dosing of male and female juvenile rats did not produce memory deficits at 91-fold the human exposure. 
Odmerjanje dulaglutida mladim podganjim samcem in samicam, ki je bilo 91-krat večje od izpostavljenosti pri človeku, ni povzročilo okvar spomina.
The mean apparent clearance of dulaglutide 0.75 mg and 1.5 mg at steady state was 0.111 L/h and 0.107 L/h with an elimination half-life of 4.5 and 4.7 days, respectively. 
Povprečni navidezni očistek dulaglutida 0,75 mg in 1,5 mg v stanju dinamičnega ravnovesja je bil 0,111 l/h in 0,107 l/h z razpolovnim časom izločanja 4,5 in 4,7 dni.
A similar percentage of patients achieved HbA1c targets of < 8.0 % at 26 and 52 weeks with both dulaglutide doses as well as insulin glargine. 
Podoben odstotek bolnikov je dosegel ciljne vrednosti HbA1c < 8,0 % v 26. in 52. tednu, tako z odmerki dulaglutida kot insulina glargina.
Following coadministration of multiple dose dulaglutide with steady state metformin (immediate release formula [IR]), metformin AUCτ increased up to 15 % and Cmax decreased up to 12 %, respectively, with no changes in tmax. 
(zdravilo s takojšnjim sproščanjem [IR - immediate release]), je AUCτ metformina narasla do 15 %, Cmax pa se je zmanjšal do 12 %, brez sprememb v tmax.
This medicinal product contains less than 1 mmol sodium (23 mg) per 1.5 mg dose, i.e. essentially ‘sodium- free'. 
Vsebnost natrija To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek 1,5 mg, kar v bistvu pomeni »brez natrija«.
In a 52 week study, Trulicity 1.5 mg and 0.75 mg were compared to titrated insulin glargine as add-on to prandial insulin lispro to evaluate the effect on glycaemic control and safety of patients with moderate to severe chronic kidney disease (eGFR [by CKD-EPI] <60 and ≥15 mL/min/1.73 m2). 
Uporaba pri bolnikih z okvarjenim delovanjem ledvic V 52-tedenski študiji so odmerka zdravila Trulicity 1,5 mg in 0,75 mg primerjali s titriranim insulinom glarginom kot dodatkom prandialnemu insulinu lispro, za ocenjevanje učinka na glikemični nadzor in varnost bolnikov z zmerno do hudo ledvično boleznijo (eGFR [po CKD-EPI] < 60 in ≥ 15 ml/min/1,73 m2).
If there are less then 3 days before your next dose is due, skip the dose and inject the next one on your regular scheduled day. 
Če pa ostanejo manj kot 3 dnevi do vašega naslednjega predpisanega odmerka, preskočite odmerek in vzemite naslednji odmerek na naslednji predpisani dan.
Cases of anaphylactic reaction have been rarely reported with marketed use of dulaglutide. 
V času trženja dulaglutida so redko poročali o primerih anafilaktične reakcije.
These observations are not clinically relevant. 
Te ugotovitve niso klinično pomembne.
Marketing Authorisation Holder Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands. 
Imetnik dovoljenja za promet z zdravilom Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology or repeat-dose toxicity. 
Neklinični podatki na osnovi običajnih študij farmakološke varnosti in toksičnosti pri ponavljajočih se odmerkih ne kažejo posebnega tveganja za človeka.
Please read these Instructions for use and the Information for the patient carefully and completely before using your pre-filled syringe. 
Natančno in v celoti preberite ta navodila za uporabo in navodilo za bolnika, preden začnete z uporabo svoje napolnjene injekcijske brizge Trulicity.
• Store your syringe in the refrigerator. 
• Svoj peresnik shranjujte v hladilniku.
• If you have any questions or problems with your Trulicity pen, contact your doctor, pharmacist or nurse. 
• Če imate vprašanja ali težave z vašo napolnjeno injekcijsko brizgo Trulicity, se obrnite na zdravnika, farmacevta ali medicinsko sestro.
1 UNCAP Pull off and discard the needle cover. 
• Snemite in zavrzite pokrovček igle.
What you need to know before you use Trulicity 
Kaj morate vedeti, preden boste uporabili zdravilo Trulicity Ne uporabljajte zdravila Trulicity
Type 2 diabetes patients were randomly allocated to either Trulicity 1.5 mg (4,949) or placebo (4,952) both in addition to standards of care for type 2 diabetes (the 0.75 mg dose was not administered in this study). 
Bolnikom s sladkorno boleznijo tipa 2 je bilo naključno dodeljeno zdravljenje z zdravilom Trulicity 1,5 mg (4949) ali s placebom (4952), oboje poleg standardnega zdravljenja za sladkorno bolezen tipa 2.
It is unknown whether dulaglutide is excreted in human milk. 
Ni znano, ali se dulaglutid izloča v materino mleko.
Dulaglutide improves glycaemic control through the sustained effects of lowering fasting, pre-meal and postprandial glucose concentrations in patients with type 2 diabetes starting after the first dulaglutide administration and is sustained throughout the once weekly dosing interval. 
Dulaglutid izboljšuje glikemično urejenost prek trajnih učinkov zniževanja koncentracije glukoze pri bolnikih s sladkorno boleznijo tipa 2, in sicer koncentracije glukoze na tešče, pred obroki in po zaužitju hrane.
Drops of liquid on the tip of the needle are not unusual and will not affect your dose. 
Kapljice tekočine niso nič neobičajnega in ne bodo vplivale na vaš odmerek.
Dulaglutide 1.5 mg once weekly and insulin glargine (n=150) 
Dulaglutid 1,5 mg enkrat na teden in insulin glargin (n=150)
A significant and sustained reduction in HbA1c levels from baseline to month 60 was observed with Trulicity vs placebo, in addition to standard of care (-0.29 % vs 0.22 %; estimated treatment difference -0.51 % [-0.57; -0.45]; p < 0.001). 
Pri zdravilu Trulicity so v primerjavi s placebom (oboje so bolniki prejemali poleg standardnega zdravljenja), opazili pomembno in trajno znižanje vrednosti HbA1c od izhodišča do 60. meseca (-0,29 % v primerjavi z 0,22 %; ocenjena razlika med zdravljenjema -0,51 % [-0,57; -0,45]; p < 0,001).
The severe hypoglycaemia event incidences were 2.4% and 3.4%, and rates were 0.05 and 0.06 events/patient/year. 
Pojavnost dogodkov hude hipoglikemije je znašala 2,4 % oziroma 3,4 %, stopnje pa 0,05 oziroma 0,06 dogodkov/bolnika/leto.
A drop of liquid on the tip of the needle is not unusual and will not affect your dose. 
Kapljica tekočine ni nič neobičajnega in ne bo vplivala na vaš odmerek.
Contact your doctor if you have any questions or concerns. 
V primeru vprašanj ali pomislekov se obrnite na zdravnika.